Guyasuta Investment Advisors Inc. lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 119,436 shares of the medical research company’s stock after buying an additional 2,132 shares during the period. Thermo Fisher Scientific accounts for approximately 3.6% of Guyasuta Investment Advisors Inc.’s portfolio, making the stock its 5th largest holding. Guyasuta Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $35,076,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. ACG Wealth increased its position in Thermo Fisher Scientific by 0.5% during the second quarter. ACG Wealth now owns 17,137 shares of the medical research company’s stock worth $5,033,000 after purchasing an additional 90 shares during the last quarter. Enlightenment Research LLC acquired a new position in Thermo Fisher Scientific during the second quarter worth approximately $214,000. Alpine Woods Capital Investors LLC increased its position in Thermo Fisher Scientific by 13.9% during the second quarter. Alpine Woods Capital Investors LLC now owns 9,864 shares of the medical research company’s stock worth $2,897,000 after purchasing an additional 1,200 shares during the last quarter. Meridian Management Co. increased its position in Thermo Fisher Scientific by 5.2% during the second quarter. Meridian Management Co. now owns 11,297 shares of the medical research company’s stock worth $3,318,000 after purchasing an additional 557 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its position in Thermo Fisher Scientific by 33.3% during the second quarter. Teacher Retirement System of Texas now owns 140,901 shares of the medical research company’s stock worth $41,380,000 after purchasing an additional 35,173 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently commented on TMO shares. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, May 30th. They set an “outperform” rating for the company. UBS Group upped their price target on shares of Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Needham & Company LLC upped their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus target price of $303.17.

In related news, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total transaction of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total transaction of $14,241,500.00. Following the sale, the chief executive officer now directly owns 342,193 shares of the company’s stock, valued at $97,466,832.19. The disclosure for this sale can be found here. Insiders sold 52,775 shares of company stock valued at $14,986,676 in the last three months. Company insiders own 0.45% of the company’s stock.

Shares of Thermo Fisher Scientific stock traded down $0.94 during trading hours on Thursday, hitting $277.33. The company’s stock had a trading volume of 24,578 shares, compared to its average volume of 1,573,977. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $305.45. The business has a fifty day moving average of $285.29 and a 200 day moving average of $272.55. The company has a market capitalization of $111.94 billion, a PE ratio of 24.94, a P/E/G ratio of 1.83 and a beta of 1.11. The company has a quick ratio of 1.07, a current ratio of 1.49 and a debt-to-equity ratio of 0.58.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The company had revenue of $6.32 billion during the quarter, compared to analyst estimates of $6.31 billion. During the same quarter in the prior year, the business earned $2.75 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 12.24 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.27%. The ex-dividend date is Monday, September 16th. Thermo Fisher Scientific’s payout ratio is currently 6.83%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: How Investors Can Profit from Options Trading

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.